Related Articles
Nivolumab With Nab-Paclitaxel Offers a Potential New Option in MIBC
Combination nivolumab and nab-paclitaxel may be a safe and effective treatment for patients with muscle-invasive bladder cancer.
Inclusion of PSMA-PET to mpMRI May Better Clinical Evaluation of Patients on Active Surveillance
The addition of PSMA-PET imaging to multi-parametric MRI was associated with an improvement in the detection of clinically significant prostate cancer.
5-Year Data Confirms Long-Term Benefits of Nadofaragene Firadenovec in NMIBC
Nadofaragene firadenovec maintained its durable clinical activity at 5 years in patients with high-risk, BCG-unresponsive non–muscle-invasive bladder cancer.
Second-Line Medications and Toxicities in GVHD
A medical expert delves into various aspects of second-line therapies, including dose reductions, potential adverse reactions, and the possibility of transfusions, all of which are…
In mCRPC, Prior Abiraterone Treatment Plus Lutetium Lu 177 Vipivotide Tetraxetan Improves Outcomes
Improved outcomes with lutetium Lu 177 vipivotide tetraxetan vs ARPI change supported prior treatment with abiraterone vs enzalutamide in mCRPC.
EG-70 Elicits Promising Complete Responses in NMIBC
EG-70, a novel, nonviral gene therapy, elicited a 73% complete response at any time for patients with non-muscle invasive bladder cancer (NMIBC) with carcinoma in…
Spira on the MARIPOSA Trial of Amivantamab/Lazertinib in EGFRm NSCLC
Alex Spira, MD, PhD, discusses a subset analysis of the phase 3 MARIPOSA trial looking at dose interruptions during the course of amivantamab and lazertinib…
Durable Responses Seen with TAR-200 in BCG-Unresponsive NMIBC
Treatment with TAR-200 displayed a high complete response rate in Bacillus Calmette-Guérin-unresponsive high-risk non-muscle-invasive bladder cancer.
No Benefit in DFS or OS Seen With Extended Lymphadenectomy vs Standard in Urothelial Cancer
Patients who underwent extended lymph node dissection during radical cystectomy compared with those who underwent standard lymph node dissection exhibited no benefit in disease-free survival…
Acalabrutinib Combo Improves PFS Over Standard of Care in Mantle Cell Lymphoma
Acalabrutinib plus bendamustine and rituximab bettered progression-free survival over bendamustine and rituximab alone in patients with untreated mantle cell lymphoma.